PDCD1 and neoplasm: In order to determine the effect of the activation state in peripheral blood lymphocytes on anti-PD-1 tumor immunotherapy, we randomly selected five NSCLC patients whose the percentages of CD69+ cells in peripheral blood T cells were greater than 5% (CD69high group) and five NSCLC patients whose the percentages of CD69+ cells in peripheral blood T cells were less than 5% (CD69low group).